AR072787A1 - Compuestos y composiciones como inhibidores de cinasa - Google Patents

Compuestos y composiciones como inhibidores de cinasa

Info

Publication number
AR072787A1
AR072787A1 ARP090102347A ARP090102347A AR072787A1 AR 072787 A1 AR072787 A1 AR 072787A1 AR P090102347 A ARP090102347 A AR P090102347A AR P090102347 A ARP090102347 A AR P090102347A AR 072787 A1 AR072787 A1 AR 072787A1
Authority
AR
Argentina
Prior art keywords
alkyl
halogen
optionally substituted
nrr7
alkoxy
Prior art date
Application number
ARP090102347A
Other languages
English (en)
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irm Llc filed Critical Irm Llc
Publication of AR072787A1 publication Critical patent/AR072787A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Derivados de pirimidina y composiciones farmacéuticas de los mismos, y métodos para utilizar estos compuestos. Por ejemplo, los derivados de pirimidina de la presente se pueden utilizar para tratar, aminorar o prevenir una condicion que responda a la inhibicion de factor de crecimiento tipo insulina (IGF-1R) o de la cinasa de linfoma anaplásico (ALK). Reivindicacion 1: Un compuesto de la formula (1), o una sal fisiologicamente aceptable del mismo; en donde el anillo E puede contener opcionalmente un doble enlace; uno de Z1, Z2 y Z3 es NR6, N(R6)+-O- o S(O)1-2 y los otros son CR2; R1 es halogeno o un alquilo C1-6 opcionalmente halogenado; R2 es piridin-2-onilo, azepan-2-onilo o un heteroarilo monocíclico de 5 a 6 miembros que tiene de 1 a 3 heteroátomos seleccionados a partir de N, O y S; cada uno de los cuales está opcionalmente sustituido con R9 en donde R9 es alquilo C1-6, haloalquilo C1-6 o cicloalquilo C3-7; R3 y R4 son cada uno H; R5 es halogeno, hidroxilo, alquilo C1-6, alcoxilo C1-6, alquilo C1-6 sustituido por halogeno, alcoxilo C1-6 sustituido por halogeno, ciano o C(O)O0-1R8; R6 es H; alquilo C1-6, alquenilo C2-6 o alquinilo C2-6, cada uno de los cuales puede estar opcionalmente sustituido con grupos halogeno y/o hidroxilo; -(CR2)p-OR7, -(CR2)p-CH(OH)CtF2t+1 en donde t es de 1 a 3, -(CR2)p-CN, -(CR2)p-NR(R7), -(CR2)p-C(O)OR7, -(CR2)pNR(CR2)pOR7, -(CR2)pNR-L-C(O)R8, -C(O)-(CR2)qOR8, -C(O)O-(CR2)p-NRR7, -C(O)-(CR2)p-OR7, -L-Y, -L-C(O)R7, -L-C(O)-NRR7, -L-C(O)-NR-(CR2)p-NRR7, -L-C(O)NR(CR2)pOR7, -L-C(O)-(CR2)q-NR-C(O)-R8, -L-C(O)NR(CR2)pSR7, -L-C(O)NR(CR2)pS(O)1-2R8, -L-S(O)2R8, -L-S(O)2-(CR2)q-NRR7, -L-S(O)2NR(CR2)pNR(R7) o -L-S(O)2NR(CR2)pOR7; de una manera alternativa, R6 es un radical seleccionado a partir de la formula (a), (b), (c) o (d); R10 es O, S, NR17 en donde R17 es H, alquilo C1-6, SO2R8a o CO2R8a; R11, R12, R13, R14, R15 y R16 se seleccionan independientemente a partir de H; alcoxilo C1-6; alquilo C1-6, alquenilo C2-6, o alquinilo C2-6, cada uno de los cuales puede estar opcionalmente sustituido con grupos halogeno, amino o hidroxilo; o R11 y R12, R12 y R15, R15 y R16, R13 y R14, o R13 y R15, junto con los átomos con los que están unidos, pueden formar un anillo de 3 a 7 miembros, saturado, insaturado, o parcialmente insaturado que contiene de 1 a 3 heteroátomos seleccionados a partir de N, O y S, y opcionalmente sustituido con oxo y de 1 a 3 grupos R5; L es (CR2)1-4 o un enlace; Y es un anillo carbocíclico C3-7, arilo C6-10, o un heteroarilo de 5 a 10 miembros o anillo heterocíclico de 4 a 10 miembros, cada uno de los cuales está opcionalmente sustituido con 1 a 3 grupos R5; R7, R8 y R8a son independientemente alquilo C1-6, alquenilo C2-6, o alquinilo C2-6, cada uno de los cuales puede estar opcionalmente sustituido con halogeno, amino, hidroxilo o ciano; (CR2)qY o alcoxilo C1-6; o R7 es H; cada R es independientemente H o alquilo C1-6; R y R7 junto con N en cada NRR7 pueden formar un anillo de 5 a 6 miembros que contiene de 1 a 3 heteroátomos seleccionados a partir de N, O y S, y opcionalmente sustituido con oxo y de 1 a 3 grupos R5; m es de 2 a 4; n es de 1 a 3; p es de 1 a 4; y q es de 0 a 4.
ARP090102347A 2008-06-25 2009-06-25 Compuestos y composiciones como inhibidores de cinasa AR072787A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7558308P 2008-06-25 2008-06-25
US15543409P 2009-02-25 2009-02-25

Publications (1)

Publication Number Publication Date
AR072787A1 true AR072787A1 (es) 2010-09-22

Family

ID=41349515

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090102347A AR072787A1 (es) 2008-06-25 2009-06-25 Compuestos y composiciones como inhibidores de cinasa

Country Status (29)

Country Link
US (2) US8519129B2 (es)
EP (1) EP2318392A2 (es)
JP (1) JP5508412B2 (es)
KR (1) KR101432352B1 (es)
CN (1) CN102112467B (es)
AR (1) AR072787A1 (es)
AU (1) AU2009264934B2 (es)
BR (1) BRPI0914652A2 (es)
CA (1) CA2729495C (es)
CL (1) CL2009001476A1 (es)
CO (1) CO6351787A2 (es)
CR (1) CR20110028A (es)
DO (1) DOP2010000397A (es)
EA (1) EA020730B1 (es)
EC (1) ECSP11010784A (es)
GE (1) GEP20125564B (es)
HN (1) HN2010002733A (es)
IL (1) IL210124A0 (es)
MA (1) MA32497B1 (es)
MX (1) MX2010014039A (es)
NI (1) NI201000219A (es)
NZ (1) NZ590602A (es)
PA (1) PA8834001A1 (es)
PE (1) PE20100087A1 (es)
SV (1) SV2010003776A (es)
TW (1) TW201000466A (es)
UY (1) UY31929A (es)
WO (1) WO2010002655A2 (es)
ZA (1) ZA201100344B (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2190826A2 (en) 2007-08-28 2010-06-02 Irm Llc 2-biphenylamino-4-aminopyrimidine derivatives as kinase inhibitors
US8445505B2 (en) 2008-06-25 2013-05-21 Irm Llc Pyrimidine derivatives as kinase inhibitors
PE20100087A1 (es) * 2008-06-25 2010-02-08 Irm Llc Compuestos y composiciones como inhibidores de cinasa
WO2011018517A1 (en) 2009-08-14 2011-02-17 Boehringer Ingelheim International Gmbh Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives
US8933227B2 (en) 2009-08-14 2015-01-13 Boehringer Ingelheim International Gmbh Selective synthesis of functionalized pyrimidines
EP2544672A1 (en) 2010-03-09 2013-01-16 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
CA2798578C (en) 2010-05-21 2015-12-29 Chemilia Ab Novel pyrimidine derivatives
PL2576541T3 (pl) 2010-06-04 2016-10-31 Pochodne aminopirymidyny jako modulatory lrrk2
LT3124483T (lt) 2010-11-10 2019-09-25 Genentech, Inc. Pirazolo aminopirimidino dariniai, kaip lrrk2 moduliatoriai
WO2012097479A1 (en) * 2011-01-21 2012-07-26 Abbott Laboratories Bicyclic inhibitors of anaphastic lymphoma kinase
US9006241B2 (en) 2011-03-24 2015-04-14 Noviga Research Ab Pyrimidine derivatives
CN105001165B (zh) 2011-04-22 2020-06-23 西格诺药品有限公司 取代的二氨基嘧啶其组合物，和用其治疗的方法
EP2554544A1 (en) * 2011-08-01 2013-02-06 Almirall, S.A. Pyridin-2(1h)-one derivatives as jak inhibitors
WO2013030750A1 (en) 2011-09-01 2013-03-07 Lupin Limited Antiviral compounds
KR101774861B1 (ko) * 2012-04-20 2017-09-05 안지 파마슈티컬 코퍼레이션 리미티드 퓨린 유도체의 사이클로프로판카르복실레이트 에스터
AU2012382373A1 (en) 2012-06-12 2014-12-11 Abbvie Inc. Pyridinone and pyridazinone derivatives
CA2890006C (en) 2012-11-06 2021-11-23 Shanghai Fochon Pharmaceutical Co Ltd Alk kinase inhibitors
CN104109149B (zh) * 2013-04-22 2018-09-28 苏州泽璟生物制药有限公司 氘代的二氨基嘧啶化合物以及包含该化合物的药物组合物
WO2015094803A1 (en) * 2013-12-16 2015-06-25 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
NZ715903A (en) 2014-01-30 2017-06-30 Signal Pharm Llc Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
US20150259420A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
WO2015180685A1 (zh) * 2014-05-30 2015-12-03 北京浦润奥生物科技有限责任公司 Alk激酶抑制剂及其制备方法和应用
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
CR20170143A (es) 2014-10-14 2017-06-19 Dana Farber Cancer Inst Inc Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas
EP3712134B1 (en) 2014-12-16 2023-11-29 Signal Pharmaceuticals, LLC Salts of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methycyclohexylamino)-pyrimidine-5-carboxamide
JP6903577B2 (ja) 2014-12-16 2021-07-14 シグナル ファーマシューティカルズ，エルエルシー 皮膚におけるｃ−Ｊｕｎ Ｎ末端キナーゼの阻害の測定方法
WO2016100882A1 (en) 2014-12-19 2016-06-23 Novartis Ag Combination therapies
CN105777616B (zh) * 2014-12-26 2018-12-07 上海医药工业研究院 色瑞替尼的合成中间体及其制备方法
WO2016123291A1 (en) 2015-01-29 2016-08-04 Signal Pharmaceuticals, Llc Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
SG11201706756VA (en) 2015-03-10 2017-09-28 Aduro Biotech Inc Compositions and methods for activating "stimulator of interferon gene" -dependent signalling
JP6805232B2 (ja) 2015-07-24 2020-12-23 セルジーン コーポレイション （１ｒ，２ｒ，５ｒ）−５−アミノ−２−メチルシクロヘキサノール塩酸塩の合成方法及びそれに有用な中間体
WO2017019897A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to tim-3
EP4378957A2 (en) 2015-07-29 2024-06-05 Novartis AG Combination therapies comprising antibody molecules to pd-1
DK3317301T3 (da) 2015-07-29 2021-06-28 Immutep Sas Kombinationsterapier omfattende antistofmolekyler mod lag-3
EP3370768B9 (en) 2015-11-03 2022-03-16 Janssen Biotech, Inc. Antibodies specifically binding pd-1 and their uses
CN108495651A (zh) 2015-12-17 2018-09-04 诺华股份有限公司 抗pd-1的抗体分子及其用途
EP3507367A4 (en) 2016-07-05 2020-03-25 Aduro BioTech, Inc. CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
WO2018237173A1 (en) 2017-06-22 2018-12-27 Novartis Ag ANTIBODY MOLECULES DIRECTED AGAINST CD73 AND CORRESPONDING USES
AR126019A1 (es) 2018-05-30 2023-09-06 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
WO2020069208A1 (en) * 2018-09-27 2020-04-02 The Regents Of The University Of California Prevention and treatment of osteoarthritis by inhibition of insulin growth factor-1 signaling
WO2020259683A1 (zh) * 2019-06-28 2020-12-30 成都赜灵生物医药科技有限公司 2，4-二取代嘧啶衍生物及其制备方法和用途
WO2021053559A1 (en) 2019-09-18 2021-03-25 Novartis Ag Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
GB201915618D0 (en) 2019-10-28 2019-12-11 Univ Oslo ALK inhibitors for treatment of ALK-negative cancer and antibody-mediated diseases
CN114685616B (zh) * 2020-12-31 2024-03-29 哈尔滨三联药业股份有限公司 醋酸曲普瑞林的合成方法
CN114276331B (zh) * 2022-01-04 2023-05-23 中国药科大学 4-氨基哌啶类化合物及其制备方法、药物组合物和应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2274634T3 (es) 1998-08-29 2007-05-16 Astrazeneca Ab Compuestos de pirimidina.
WO2001007027A2 (en) 1999-07-22 2001-02-01 Vertex Pharmaceuticals Incorporated Pyrimidine derivatives for the treatment of viral diseases
US20030004174A9 (en) 2000-02-17 2003-01-02 Armistead David M. Kinase inhibitors
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
US6939874B2 (en) 2001-08-22 2005-09-06 Amgen Inc. Substituted pyrimidinyl derivatives and methods of use
WO2003026666A1 (en) 2001-09-26 2003-04-03 Bayer Pharmaceuticals Corporation 2-phenylamino-4- (5-pyrazolylamino)-pyrimidine derivatives as kinase inhibitors, in particular, as src kinase inhibitors
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
CA2523125A1 (en) 2003-03-25 2004-10-14 Vertex Pharmaceuticals Incorporated Thiazoles useful as inhibitors of protein kinases
PT1656372E (pt) 2003-07-30 2013-06-27 Rigel Pharmaceuticals Inc Métodos para o tratamento ou prevenção de doenças autoimunes com compostos de 2,4-pirimidinadiamina
WO2005016894A1 (en) 2003-08-15 2005-02-24 Novartis Ag 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
GB0321710D0 (en) 2003-09-16 2003-10-15 Novartis Ag Organic compounds
CA2538413A1 (en) 2003-09-18 2005-03-24 Novartis Ag 2,4-di (phenylamino) pyrimidines useful in the treatment of proliferative disorders
JP5208516B2 (ja) * 2004-12-30 2013-06-12 エグゼリクシス， インコーポレイテッド キナーゼモジュレーターとしてのピリミジン誘導体および使用方法
WO2007027238A2 (en) 2005-05-03 2007-03-08 Rigel Pharmaceuticals, Inc. Jak kinase inhibitors and their uses
KR100700676B1 (ko) 2005-06-24 2007-03-28 (주) 비엔씨바이오팜 6―（4―치환된―아닐리노）피리미딘 유도체, 그 제조방법및 이를 포함하는 항바이러스용 약학적 조성물
WO2007031829A2 (en) 2005-09-15 2007-03-22 Orchid Research Laboratories Limited Novel pyrimidine carboxamides
CN103626742B (zh) 2005-11-01 2017-04-26 塔格根公司 激酶的联-芳基间-嘧啶抑制剂
AU2007269540B2 (en) * 2006-07-05 2013-06-27 Exelixis, Inc. Methods of using IGF1R and Abl kinase modulators
CL2007002231A1 (es) 2006-08-02 2008-04-11 Basf Ag Uso de compuestos derivados de 5-(het) arilpirimidina para combatir hongos daninos; compuestos derivados de 5-(het) arilpirimidina; agente fungicida; y agente farmaceutico.
ES2597453T3 (es) 2006-08-15 2017-01-18 Xenon Pharmaceuticals Inc. Compuestos heterocíclicos adecuados para el tratamiento de enfermedades relacionadas con un elevado nivel de lípidos
WO2008051547A1 (en) 2006-10-23 2008-05-02 Cephalon, Inc. Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and c-met inhibitors
NZ577197A (en) * 2006-12-08 2011-02-25 Irm Llc Pyrimidine compounds especially 4-phenylamino-2-arylamino-pyrimidine derivatives and compositions as protein kinase inhibitors
PT2091918E (pt) 2006-12-08 2014-11-24 Irm Llc Compostos e composições como inibidores de proteína cinase
WO2008083465A1 (en) 2007-01-08 2008-07-17 University Health Network Pyrimidine derivatives as anticancer agents
WO2009017838A2 (en) 2007-08-01 2009-02-05 Exelixis, Inc. Combinations of jak-2 inhibitors and other agents
EP2190826A2 (en) * 2007-08-28 2010-06-02 Irm Llc 2-biphenylamino-4-aminopyrimidine derivatives as kinase inhibitors
PE20091236A1 (es) 2007-11-22 2009-09-16 Astrazeneca Ab Derivados de pirimidina como immunomoduladores de tlr7
RU2010137300A (ru) 2008-02-22 2012-03-27 Ф. Хоффманн-Ля Рош Аг (Ch) Модуляторы бета-амилоида
PE20100087A1 (es) * 2008-06-25 2010-02-08 Irm Llc Compuestos y composiciones como inhibidores de cinasa
US8445505B2 (en) * 2008-06-25 2013-05-21 Irm Llc Pyrimidine derivatives as kinase inhibitors

Also Published As

Publication number Publication date
BRPI0914652A2 (pt) 2017-06-06
EP2318392A2 (en) 2011-05-11
NI201000219A (es) 2011-05-24
UY31929A (es) 2010-01-05
TW201000466A (en) 2010-01-01
PA8834001A1 (es) 2010-04-21
WO2010002655A2 (en) 2010-01-07
US20130310361A1 (en) 2013-11-21
ZA201100344B (en) 2012-10-31
CA2729495A1 (en) 2010-01-07
AU2009264934B2 (en) 2012-09-27
HN2010002733A (es) 2013-01-28
KR20110022699A (ko) 2011-03-07
AU2009264934A1 (en) 2010-01-07
US20110112063A1 (en) 2011-05-12
MA32497B1 (fr) 2011-07-03
CA2729495C (en) 2013-12-17
SV2010003776A (es) 2012-01-04
DOP2010000397A (es) 2011-01-15
CO6351787A2 (es) 2011-12-20
NZ590602A (en) 2011-10-28
JP5508412B2 (ja) 2014-05-28
EA020730B1 (ru) 2015-01-30
KR101432352B1 (ko) 2014-08-21
CN102112467B (zh) 2014-04-30
US8859574B2 (en) 2014-10-14
PE20100087A1 (es) 2010-02-08
JP2011526284A (ja) 2011-10-06
EA201100077A1 (ru) 2011-08-30
ECSP11010784A (es) 2011-02-28
CN102112467A (zh) 2011-06-29
GEP20125564B (en) 2012-06-25
CR20110028A (es) 2011-04-07
MX2010014039A (es) 2011-01-21
WO2010002655A3 (en) 2010-04-01
IL210124A0 (en) 2011-02-28
CL2009001476A1 (es) 2010-01-11
US8519129B2 (en) 2013-08-27

Similar Documents

Publication Publication Date Title
AR072787A1 (es) Compuestos y composiciones como inhibidores de cinasa
ES2570127T3 (es) Compuestos y composiciones como inhibidores de la proteína quinasa
AR074782A1 (es) Antranilamidas sustituidas con tetrazol como plaguicidas
AR049388A1 (es) Heterociclos como inhibidores de aldosterona sintasa
PE20141827A1 (es) Inhibidores de proteinas quinasas
AR060050A1 (es) Compuestos moduladores del receptor de s1p y uso de los mismos
AR061974A1 (es) Derivados de pirimidina como inhibidores de alk, composiciones farmaceuticas y procesos de obtencion
AR059571A1 (es) Derivados de octahidro-pirrolo[3,4-c]pirrol, composiciones farmaceuticas
AR056536A1 (es) Compuestos de 2-amino-5- [4-(difluormetoxi)fenil]-5-fenilimidazolona como inhibidores de la beta secretasa (bace)
AR067327A1 (es) Derivados de piperidina / piperazina
AR066911A1 (es) Derivados de piperidina / piperazina
AR076067A1 (es) Composiciones y metodos para modular la senda de senalizacion de wnt
AR082029A1 (es) Derivados de heterociclos nitrogenados, composiciones y metodos para modular la via de señalizacion de wnt
AR081058A1 (es) Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer.
AR066153A1 (es) Derivados de piperidina / piperazina
ES2393824T3 (es) Derivados de piridin-2-il-amino-1,2,4-tiadiazol como activadores de glucoquinasa para el tratamiento de diabetes mellitus
AR079498A1 (es) Derivados de 2-arilimidazol heteroaromaticos como inhibidores de enzima pde10a
AR047538A1 (es) Piridazinonas como antagonistas de las integrinas alfa4
AR079205A1 (es) Morfolinotiazoles como moduladores alostericos positivos alfa 7
AR072166A1 (es) Derivado de piperidina y su uso como inhibidor de renina superior
AR073450A1 (es) Combinaciones de drogas que comprenden un inhibidor de dgat y un agonista de ppar
AR069435A1 (es) Derivados de aminotiazol, proceso para la obtencion de los mismos, composiciones farmaceuticas y su uso como inhibidores de la fbpasa
CO6251263A2 (es) Derivados de bencimidazol e indol sustutuidos por oxadiazol y oxazol como inhibidores de dgat1
UY32463A (es) Derivados de (1-{[5-(4-halo-2-trifluorometil-fenilamino)piridin-2-ilmetil]-carbamoil -ciclopropil)-amidas de ácidos pirimidin-carboxílicos y similares; sus enantiómeros, sus diastereoisómeros, y sus sales, fisiológicamente tolerables.
AR054529A1 (es) Derivados de benzazepina como moduladores del receptor de 5-hidroxi-triptamina 6

Legal Events

Date Code Title Description
FA Abandonment or withdrawal